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Background
The ability to analyze cryopreserved PBMC for antigen
specific T-cells immunity is needed in evaluating response
to immune based therapies. Comprehensive studies have
demonstrated that the quality of frozen PBMC is critical
and maintaining cell viability and functionality by using
appropriate cryopreservation techniques is a key to the
successful outcome of assays using PBMC. Different cryo-
media additives impact the cell viability. The most com-
mon additive is FCS although it has been recognized that
lots used for this purpose have to be chosen based on care-
ful testing to avoid using serum that may lead to nonspe-
cific stimulation of T-cells. In addition, the most widely
used cryopreservation procedure for cells is based on add-
ing DMSO. However, the amount of DMSO added must
be reduced significantly due to its toxic impact on cells at
room temperature. Therefore, we have developed novel
freezing approaches aiming at the use of cryoprotectants
having minimum cytotoxicity and maintaining T-cell
functionality.
Methods
To measure the resulting PBMC recovery and viability, we
have used trypan blue exclusion and FACS analysis by
staining with propidium iodide as read-out systems. To
measure T-cell functionality, we have used the interferon-
γ ELISpot assay.
Results
We found that DMSO concentration can be reduced by
addition of hydroxyethyl starch. We also tested different
protein additives in comparison to the widely used FCS
and found that bovine serum albumin (BSA) is an appro-
priate additive to substitute the potential immune modu-
lating FCS. Using our new cryomedia, the PBMC recovery
is more than 80% and the PBMC viability is more than
97%. Also the T-cell functionality measured by ELISpot is
optimal with our new cryomedia.
Conclusion
Based on our experimental results, we could finally design
two different, optimized cryomedia. Both media are
standardized serum-free and manufactured under GMP
conditions. In addition, one media contains a reduced
amount of the DMSO.
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